RESUMEN
We have developed a surface plasmon resonance (SPR) system to monitor the cross-bridge attachment/detachment process within intact sarcomeres from mouse heart muscle. SPR occurs when laser light energy is transferred to surface plasmons that are resonantly excited in a metal (gold) film. This resonance manifests itself as a minimum in the reflection of the incident laser light and occurs at a characteristic angle. The angle of the SPR occurrence depends on the dielectric permittivity of the sample medium adjacent to the gold film. Purified sarcomeric preparations are immobilized onto the gold film in the presence of a relaxing solution. Replacement of the relaxing solution with increasing Ca(2+) concentration solution activates the cross-bridge interaction and produces an increase in the SPR angle. These results imply that the interaction of myosin heads with actin within an intact sarcomere changes the dielectric permittivity of the sarcomeric structure. In addition, we further verify that SPR measurements can detect the changes in the population of the attached cross-bridges with altered concentrations of phosphate, 2,3-butanedione monoxime, or adenosine triphosphate at a fixed calcium concentration, which have been shown to reduce the force and increase the cross-bridge population in attached state. Thus, our data provide the first evidence that the SPR technique allows the monitoring of the cross-bridge attachment/detachment process within intact sarcomeres.
Asunto(s)
Diacetil/análogos & derivados , Sarcómeros/química , Sarcómeros/metabolismo , Resonancia por Plasmón de Superficie/métodos , Adenosina Trifosfato/metabolismo , Animales , Calcio/química , Compuestos Cromogénicos/química , Dextranos/química , Diacetil/química , Relación Dosis-Respuesta a Droga , Ratones , Modelos Químicos , Miocardio/química , Miocardio/metabolismo , Fosfatos/química , Soluciones , Resonancia por Plasmón de Superficie/instrumentaciónAsunto(s)
Endotelio Vascular/fisiología , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Neovascularización Fisiológica/fisiología , Óxido Nítrico Sintasa/metabolismo , Receptores de Bradiquinina/metabolismo , Animales , Comunicación Autocrina , Bradiquinina/farmacología , División Celular , Córnea/irrigación sanguínea , Microcirculación , Modelos Biológicos , Conejos , Receptor de Bradiquinina B1 , Fosfolipasas de Tipo C/metabolismoRESUMEN
Integrin-mediated endothelial cell-extracellular matrix adhesion plays a critical role in maintaining the structural integrity of microvascular walls. The aim of this study was to evaluate the impact of specific integrin extracellular domain binding to matrix fibronectin and vitronectin on the barrier function of intact microvascular endothelium. The apparent permeability coefficient of albumin was measured in isolated and perfused porcine coronary venules using a fluorescence ratioing technique with the aid of fluorescence microscopy. Inhibition of integrin binding to either fibronectin with GRGDdSP peptide or vitronectin with GPenGRGDSPCA peptide dose-dependently increased venular permeability by 2- to 3-fold. The effects were sustained for more than 60 min and were reversible upon clearance of the peptides. In contrast, the inactive control peptide GRADSP did not significantly affect venular permeability. Pretreatment of the venules with purified human fibronectin and vitronectin, respectively, prevented the hyperpermeability response to GRGDdSP and GPenGRGDSPCA. GRGDSP, a peptide that inhibits integrin binding to both fibronectin and vitronectin, produced an even higher permeability (4.5-fold) in venules than GRGDdSP or GPenGRGDSPCA alone, and the effect was blunted in vessels preincubated with both fibronectin and vitronectin. The results indicate the importance of integrin-matrix interaction in the physiological regulation of microvascular permeability. It is likely that both fibronectin and vitronectin binding to integrins contribute to the maintenance of endothelial barrier function in venules.
Asunto(s)
Vasos Coronarios/metabolismo , Fibronectinas/metabolismo , Integrinas/metabolismo , Vitronectina/metabolismo , Animales , Permeabilidad de la Membrana Celular/efectos de los fármacos , Permeabilidad de la Membrana Celular/fisiología , Vasos Coronarios/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Proteínas de la Matriz Extracelular/metabolismo , Proteínas de la Matriz Extracelular/farmacología , Fibronectinas/farmacología , Técnicas In Vitro , Microcirculación/fisiología , Oligopéptidos/farmacología , Unión Proteica/fisiología , Porcinos , Vitronectina/farmacologíaRESUMEN
The vasodilator activity of alpha(1)-adrenoceptor agonists was tested in the rat mesenteric vascular bed (MVB), and the mechanism involved was investigated in cultured endothelial cells isolated from the bovine coronary vascular bed. In preparations preconstricted by U46619, noradrenaline and phenylephrine induced a slight relaxant effect at nanomolar concentrations. This effect was abolished in endothelium-denuded preparations and in preparations pretreated with 100 microM N(omega)-nitro-L-arginine methyl ester plus 3 microM indomethacin. Both the phospholipase C inhibitor U73122 and the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin inhibited the vasorelaxant effect of phenylephrine. The cellular level of inositol monophosphate (IP(1)) in bovine endothelial cells doubled after a 15-min exposure to 0.03 to 0.1 nM phenylephrine. The activity of cNOS was significantly increased following exposure to the same concentrations of phenylephrine. Both chloroethylclonidine and the selective alpha(1D)-adrenoceptor antagonist BMY 7378 reduced, in a concentration-dependent manner, the relaxant effect induced by phenylephrine, whereas the selective alpha(1A)-adrenoceptor antagonist (+)-niguldipine was ineffective. BMY 7378 also blocked the cNOS activation induced by phenylephrine. Conversely, the increase in perfusion pressure induced by micromolar concentrations of phenylephrine was blocked by 1 nM (+)-niguldipine, but was unaffected by BMY 7378. These findings demonstrate that nanomolar concentrations of phenylephrine, which are devoid of any contractile effect, induced a slight endothelium-dependent vasorelaxation in the rat MVB through the stimulation of alpha(1D)-adrenoceptors, located on endothelial cells, which act through phospholipase C stimulation, followed by IP(1) generation, and nitric-oxide synthase activation. Conversely, the increase in perfusion pressure induced by micromolar concentrations of phenylephrine is attributable to the stimulation of alpha(1A)-adrenoceptors.
Asunto(s)
Endotelio Vascular/fisiología , Arterias Mesentéricas/fisiología , Receptores Adrenérgicos alfa 1/fisiología , Vasodilatación/fisiología , Agonistas de Receptores Adrenérgicos alfa 1 , Agonistas alfa-Adrenérgicos/farmacología , Animales , Bovinos , Células Cultivadas , Interacciones Farmacológicas , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/enzimología , Inhibidores Enzimáticos/farmacología , Estrenos/farmacología , Fosfatos de Inositol/metabolismo , Arterias Mesentéricas/efectos de los fármacos , Óxido Nítrico Sintasa/metabolismo , Norepinefrina/farmacología , Fenilefrina/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Isoformas de Proteínas/fisiología , Pirrolidinonas/farmacología , Ratas , Ratas Wistar , Transducción de Señal , Circulación Esplácnica , Tapsigargina/farmacología , Vasodilatación/efectos de los fármacosRESUMEN
Because of its immunosuppressive properties, interleukin-10 (IL-10) is thought to play an important role in a number of human disease states, including inflammation, autoimmunity, and transplant rejection. In this study, we demonstrate that introduction of human or viral IL-10 genes into Burkitt's lymphoma cells markedly reduced their ability to grow as subcutaneous (sc) tumors in SCID mice. In vivo assays for angiogenesis revealed an inhibition of the angiogenic capacity of the IL-10-transfected lines. Recombinant human IL-10 abolished and viral IL-10 reduced vascular endothelial growth factor (VEGF)-165-induced neovascularization. Furthermore, IL-10 blocked the VEGF- and fibroblast growth factor (FGF)-2-induced proliferation of microvascular endothelial cells in vitro. The current observations suggest a direct role for IL-10 in the prevention of angiogenesis in human lymphoid malignancies.
Asunto(s)
Linfoma de Burkitt/patología , Interleucina-10/genética , Interleucina-10/fisiología , Neovascularización Patológica/prevención & control , Animales , Linfoma de Burkitt/inmunología , Linfoma de Burkitt/prevención & control , División Celular , Línea Celular , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/citología , Factor 2 de Crecimiento de Fibroblastos/farmacología , Expresión Génica , Interleucina-10/farmacología , Células Asesinas Naturales/inmunología , Linfocinas/farmacología , Ratones , Ratones SCID , Trasplante de Neoplasias , Conejos , Proteínas Recombinantes/farmacología , Transfección , Células Tumorales Cultivadas , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularAsunto(s)
Endotelio Vascular/enzimología , Gelatinasas/metabolismo , Neovascularización Fisiológica/fisiología , Trombospondina 1/fisiología , Inhibidor Tisular de Metaloproteinasa-2/biosíntesis , Animales , Endotelio Vascular/metabolismo , Endotelio Vascular/fisiología , Factor 2 de Crecimiento de Fibroblastos/antagonistas & inhibidores , Heparina/metabolismo , Metaloproteinasa 2 de la Matriz/metabolismo , Peso Molecular , Fragmentos de Péptidos/fisiología , Conejos , Inhibidor Tisular de Metaloproteinasa-2/metabolismoAsunto(s)
Endotelio Vascular/fisiología , Neovascularización Fisiológica/fisiología , Receptores de Bradiquinina/metabolismo , Bradiquinina/metabolismo , Bradiquinina/farmacología , Antagonistas de los Receptores de Bradiquinina , División Celular/efectos de los fármacos , Movimiento Celular , Células Cultivadas , Vasos Coronarios/citología , Endotelio Vascular/citología , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo III , Proteínas Proto-Oncogénicas c-fos/metabolismo , Receptor de Bradiquinina B1 , Receptor de Bradiquinina B2 , Receptores de Bradiquinina/agonistas , Fosfolipasas de Tipo C/metabolismo , Vénulas/citologíaRESUMEN
Nebivolol is a recently developed beta-blocker provided with vasodilator properties. Because the mechanism of the putative endothelium-dependent effect of this beta-adrenoceptor blocker has not been completely elucidated, the aim of this study was to investigate the effects of nebivolol on an isolated resistance vascular bed and on cell messengers and constitutive nitric-oxide synthase activity (cNOS) in endothelial cells. Experiments were carried out using the rat mesenteric vascular bed and cultured bovine coronary postcapillary venular endothelial cells from bovine heart (CVEC). In mesenteric vascular bed preconstricted by 30 microM noradrenaline and 0.3 microM U46619, dl-nebivolol induced a concentration-dependent relaxing effect at concentrations between 3 and 30 microM; this effect was changed to a concentration-dependent vasoconstrictor response either in endothelium-denuded preparations or in intact preparations pretreated with 100 microM N(omega)-nitro-L-arginine methyl ester plus 3 microM indomethacin. The vasorelaxant effect of dl-nebivolol in preconstricted preparations was completely blocked by pretreatment either with the phospholipase C inhibitor U73122 (1 microM) or with the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin (1 microM) for 30 min. The cellular level of the inositol trisphosphate metabolite inositol monophosphate in coronary postcapillary venular endothelial cells was not affected by dl-nebivolol in the concentration range 100 nM to 1 microM, but it was concentration dependently increased after exposure for 15 min to 10 and 30 microM dl-nebivolol. The activity of cNOS was almost doubled after a 5-min exposure to 10 microM dl-nebivolol and was significantly impaired by thapsigargin and N(omega)-nitro-L-arginine methyl ester treatment, although it was unaffected by N(omega)-nitro-D-arginine methyl ester. These findings demonstrate that nebivolol, in micromolar concentrations, induces vasorelaxation through activation of inositol phosphate metabolism and stimulation of cNOS activity in endothelial cells.
Asunto(s)
Benzopiranos/farmacología , Endotelio Vascular/metabolismo , Etanolaminas/farmacología , Fosfatos de Inositol/metabolismo , Óxido Nítrico Sintasa/metabolismo , Vasodilatadores/farmacología , Animales , Bovinos , Células Cultivadas , Relación Dosis-Respuesta a Droga , Estrenos/farmacología , Técnicas In Vitro , Indometacina/farmacología , Arterias Mesentéricas/metabolismo , Miocardio/metabolismo , NG-Nitroarginina Metil Éster/farmacología , Nebivolol , Norepinefrina/farmacología , Pirrolidinonas/farmacología , Ratas , Ratas Wistar , Tapsigargina/farmacología , Factores de Tiempo , Venas/metabolismoRESUMEN
Endostatin, a C-terminal product of collagen XVIII, is a very powerful angiogenesis inhibitor. In vivo experiments in mice indicate that endostatin dramatically reduces tumor mass without causing the onset of any resistance to the treatment. Recently, a 12-aa shorter human endostatin has been purified from plasma, but is ineffective in in vitro angiogenesis assays. Here we report that the full-length human recombinant endostatin has a potent inhibitory activity in in vitro angiogenesis assays. Two powerful angiogenic factors were used to stimulate endothelial cells: FGF-2 and VEGF-165. Endostatin prevented cell growth both in the basal condition and after stimulation with FGF-2 or VEGF-165. Migration of microvascular endothelial cells toward FGF-2 or VEGF-165 was impaired, both when cells were pretreated with the inhibitor and when endostatin was added together with the growth factors. Furthermore, experiments of inhibition of proliferation performed on nonmicroendothelial cells showed that endostatin was ineffective. This study indicates that human endostatin is a potent angiogenesis inhibitor and suggests its use in human anticancer therapy.
Asunto(s)
Colágeno/farmacología , Endotelio Vascular/efectos de los fármacos , Neovascularización Fisiológica/efectos de los fármacos , Fragmentos de Péptidos/farmacología , Capilares/citología , Capilares/efectos de los fármacos , División Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Clonación Molecular , Colágeno/genética , Colágeno Tipo XVIII , Endostatinas , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/citología , Factor 2 de Crecimiento de Fibroblastos/farmacología , Humanos , Linfocinas/farmacología , Fragmentos de Péptidos/genética , Proteínas Recombinantes/farmacología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular , Vénulas/citología , Vénulas/efectos de los fármacosRESUMEN
We previously demonstrated that vascular endothelial growth factor (VEGF)-elicited increase in the permeability of coronary venules was blocked by the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). The aim of this study was to delineate in more detail the signaling pathways upstream from NO production in VEGF-induced venular hyperpermeability. The apparent permeability coefficient of albumin (Pa) and endothelial cytosolic Ca2+ concentration ([Ca2+]i) were measured in intact perfused porcine coronary venules using fluorescence microscopy. VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM). In 12 venules that displayed the [Ca2+]i response to bradykinin (10(-6) M) and ionomycin (10(-6) M), only 4 vessels responded to VEGF with a transient increase in [Ca2+]i. Furthermore, Western blot analysis of cultured human umbilical vein endothelial cells showed that VEGF increased tyrosine phosphorylation of PLC-gamma and serine phosphorylation of endothelial constitutive NO synthase (ecNOS). The hyperphosphorylation of PLC-gamma was greatly attenuated by the KDR receptor antibody and U-73122, but not by BIM or L-NMMA. In contrast, U-73122 and BIM were able to inhibit VEGF-elicited serine phosphorylation of ecNOS. The results suggest that VEGF induces venular hyperpermeability through a KDR receptor-mediated activation of PLC. In turn, ecNOS is activated by PLC-mediated PKC and/or cytosolic Ca2+ elevation stimulation.
Asunto(s)
Calcio/fisiología , Permeabilidad Capilar/efectos de los fármacos , Factores de Crecimiento Endotelial/farmacología , Linfocinas/farmacología , Proteína Quinasa C/fisiología , Fosfolipasas de Tipo C/fisiología , Vénulas/efectos de los fármacos , Animales , Calcio/metabolismo , Permeabilidad Capilar/fisiología , Células Cultivadas , Factores de Crecimiento Endotelial/metabolismo , Endotelio Vascular/citología , Endotelio Vascular/enzimología , Humanos , Técnicas In Vitro , Linfocinas/metabolismo , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo III , Fosforilación , Porcinos , Fosfolipasas de Tipo C/metabolismo , Venas Umbilicales/citología , Venas Umbilicales/enzimología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
In a broad sense, physiology is the study of the chemical and physical bases of life processes. Consequently, the evolution of our knowledge of cardiovascular functions is closely linked to the developments in many fields of science, including chemistry, physics, engineering, and biology. A cursory examination reveals that different "foundation" sciences predominated in different stages of the history of cardiovascular physiology. Today, cardiovascular physiology is poised to exploit new developments in all areas of scientific inquiry. However, cardiovascular physiologists have not always embraced the power of the multidisciplinary approach. In this brief overview of the history of cardiovascular physiology in the 20th century, the major focus is on some of the major advances in the field and the contributions of other disciplines to these developments. In addition, the forces that influenced cardiovascular science in this century and their impact on the evolution of the field in the new millennium are discussed.
Asunto(s)
Cardiología/tendencias , Fenómenos Fisiológicos Cardiovasculares , Animales , Vasos Sanguíneos/citología , Vasos Sanguíneos/fisiología , Fenómenos Fisiológicos Celulares , Electrofisiología , Corazón/fisiología , Hemodinámica/fisiología , Humanos , Biología Molecular/métodos , Miocardio/citologíaRESUMEN
The plasminogen activator system is known to play a crucial role in the angiogenesis process by modulating the adhesive properties of endothelial cells to the extracellular matrix and cell-cell interaction. In the present study, we demonstrated that the urokinase-type plasminogen activator (u-PA) induced neovascular growth in the avascular rabbit cornea and dose-dependently promoted growth, chemotaxis, and matrix invasion of cultured endothelial cells. Interaction between u-PA and its receptor appears to be mandatory for the angiogenic effect of u-PA because monoclonal antibodies anti-u-PA and anti-u-PA receptor (u-PAR) blocked the proangiogenic effects of u-PA at the endothelial cell level. We then assessed the signaling pathway activated in endothelial cells by u-PA. u-PAR activation by u-PA produced de novo synthesis of diacylglycerol (DAG) from glucose by a cytochalasin B-inhibitable mechanism, indicating the involvement of a specific glucose transporter (GLUT). Endothelial cells expressed GLUT2, whose activation was tyrosine kinase-dependent and protein kinase C (PKC)-independent. The increase of glucose uptake led to DAG production, which resulted in PKC activation/translocation. Impairment of u-PAR availability by monoclonal antibodies and by antisense oligonucleotides (aODN) against u-PAR mRNA inhibited glucose uptake, DAG neosynthesis, and PKC activation, resulting in the blockade of endothelial cell proliferation, chemotaxis, and chemoinvasion. These data suggest that u-PAR activation consequent to the binding of u-PA can be regarded as an "angiogenic switch" and disclose the possibility that an anti-u-PAR aODN strategy may efficiently target endothelial cell function to control angiogenesis in vivo.
Asunto(s)
Diglicéridos/antagonistas & inhibidores , Neovascularización Fisiológica/efectos de los fármacos , Oligonucleótidos Antisentido/genética , Oligonucleótidos Antisentido/farmacología , Receptores de Superficie Celular/genética , Activador de Plasminógeno de Tipo Uroquinasa/fisiología , Animales , División Celular/efectos de los fármacos , Movimiento Celular/fisiología , Células Cultivadas , Colágeno/efectos de los fármacos , Córnea/irrigación sanguínea , Córnea/efectos de los fármacos , Diglicéridos/biosíntesis , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiología , Activación Enzimática/fisiología , Matriz Extracelular/fisiología , Transportador de Glucosa de Tipo 2 , Humanos , Laminina/efectos de los fármacos , Proteínas de Transporte de Monosacáridos/metabolismo , Neovascularización Fisiológica/fisiología , Proteína Quinasa C/metabolismo , Proteoglicanos/efectos de los fármacos , Conejos , Receptores de Superficie Celular/metabolismo , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/farmacologíaRESUMEN
Vascular endothelial growth factor (VEGF) is an endothelium-specific, secreted protein that acts as a vasodilator, angiogenic peptide, and hyperpermeability factor. Recent reports have shown that nitric oxide synthase inhibitors block proliferation and microvascular hyperpermeability induced by VEGF. This study examined the mechanisms by which nitric oxide and its downstream signals mediate the VEGF-induced proliferative response in human umbilical vein endothelial cells (HUVECs). Nitric oxide synthase blockade by Nomega-nitro-L-arginine methyl ester prevented both the proliferative effect of VEGF and Raf-1 activation by VEGF as measured by cell counting and the capacity of immunoprecipitated Raf-1 to phosphorylate syntide 2, a Raf-1-specific synthetic substrate. VEGF-induced proliferation and Raf-1 kinase activity were also inhibited by Rp-8-pCPT-cGMPs and KT5823, inhibitors of the regulatory and catalytic subunits of cGMP-dependent protein kinase (PKG), respectively. The ability of PKG to stimulate proliferation was verified by the observation that the PKG activator, 8-pCPT-cGMPs, stimulated both Raf-1 kinase activity and endothelial proliferation in a dose-dependent manner. Furthermore, recombinant catalytically active PKG phosphorylated and activated Raf-1 in a reconstituted system. Finally, Raf-1 immunoprecipitated from VEGF-stimulated endothelial cells coprecipitated with PKG, indicating a direct protein-protein interaction in activated cells. We conclude that VEGF induces increases in both proliferation and Raf-1 kinase activity in HUVECs and these activities are dependent on NO and its downstream effector, PKG.
Asunto(s)
Carbazoles , Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/fisiología , Indoles , Linfocinas/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-raf/metabolismo , Alcaloides/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/antagonistas & inhibidores , División Celular , Células Cultivadas , GMP Cíclico/análogos & derivados , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Activación Enzimática , Humanos , Péptidos y Proteínas de Señalización Intercelular , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Péptidos/metabolismo , Fosforilación , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Transducción de Señal , Venas Umbilicales/citología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
1. Bradykinin (BK) contributes to the inflammatory response inducing vasodilation of postcapillary venules and has been demonstrated to induce neovascular growth in subcutaneous rat sponges. 2. In this study the ability of BK to stimulate cell growth and migration in cultured endothelium from coronary postcapillary venules (CVEC) has been investigated. 3. [3H]-thymidine incorporation in subconfluent and synchronised CVEC was used to monitor DNA synthesis over 24 h. BK promoted a concentration-dependent increase of DNA synthesis with maximal activity at 100 nM. At this concentration BK also induced 18 fold accumulation of c-Fos protein immunoreactivity in the nucleus within 1 h from peptide exposure. 4. The total number of cells recovered after 48 h exposure to BK was increased in a concentration-dependent manner. Maximal effect was produced by 100 nM concentration of the peptide which produced 50% increase in cell number. The selective B1 receptor agonist Des-Arg9-BK mimicked the proliferative effect of BK, while the B2 receptor agonist kallidin was devoid of any activity. The proliferation induced by BK was abolished in a concentration-dependent manner by the addition of the B1 selective antagonist Des-Arg9-Leu8-BK, while the selective B2 receptor antagonist HOE140 did not modify BK-induced growth. 5. DNA synthesis and growth promoted by a threshold concentration of fibroblast growth factor-2 (FGF-2) (0.25 nM) were potentiated by increasing concentrations of BK and Des-Arg9-BK. 6. Endothelial cell migration assessed by the Boyden Chamber procedure was not promoted by BK or the selective B1 and B2 receptor agonists. 7. These data are the first demonstration that BK promotes growth of endothelial cells from postcapillary venules. The mitogenic activity of BK involves c-Fos expression and potentiates the growth promoting effect of FGF-2. Only the B1 receptor appears to be responsible for the proliferation induced by BK and suggests that this type of receptor might be implicated in favouring angiogenesis of coronary venules.
Asunto(s)
Bradiquinina/fisiología , Endotelio Vascular/efectos de los fármacos , Factor 2 de Crecimiento de Fibroblastos/farmacología , Receptores de Bradiquinina/fisiología , Vénulas/efectos de los fármacos , Animales , Bovinos , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Replicación del ADN/efectos de los fármacos , Sinergismo Farmacológico , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Proteínas Proto-Oncogénicas c-fos/metabolismo , Receptor de Bradiquinina B1 , Receptores de Bradiquinina/agonistas , Receptores de Bradiquinina/clasificación , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Vénulas/citología , Vénulas/metabolismoRESUMEN
Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that potently stimulates vasodilation, microvascular hyperpermeability, and angiogenesis. Nitric oxide (NO) is also reported to modulate vascular tone, permeability, and capillary growth. Therefore, we hypothesized that VEGF might regulate endothelial production of NO. The production of nitrogen oxides by human umbilical vein endothelial cells (HUVECs) was measured after 1, 12, 24, and 48 h of incubation with VEGF. VEGF treatment resulted in both an acute (1 h) and chronic (> 24 h) stimulation of NO production. Furthermore, Western and Northern blotting revealed a VEGF-elicited, dose-dependent increase in the cellular content of endothelial cell nitric oxide synthase (ecNOS) message and protein that may account for the chronic upregulation of NO production elicited by VEGF. Finally, endothelial cells pretreated with VEGF for 24 h and subsequently exposed to A-23187 for 1 h produced NO at approximately twice the rate of cells that were not pretreated with VEGF. We conclude that VEGF upregulates ecNOS enzyme and elicits a biphasic stimulation of endothelial NO production.
Asunto(s)
Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/metabolismo , Linfocinas/farmacología , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico/metabolismo , Calcio/fisiología , Células Cultivadas , Relación Dosis-Respuesta a Droga , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Factores de Tiempo , Regulación hacia Arriba/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
We recently demonstrated that nitric oxide (NO) significantly contributes to the mitogenic effect of vascular endothelial growth factor (VEGF), suggesting a role for the NO pathway in the signaling cascade following kinase-derivative receptor activation in vascular endothelium. The aim of this study was to investigate the intracellular pathways linked to VEGF/NO-induced endothelial cell proliferation. We assessed the activity of the mitogen-activated protein kinase (MAPK) that is specifically activated by growth factors, extracellular-regulated kinase (ERK1/2), on cultured microvascular endothelium isolated from coronary postcapillary venules. ERK1/2 was immunoprecipitated, and its activity was assessed with an immunocomplex kinase assay. In endothelial cells exposed for 5 min to the NO donor drug sodium nitroprusside at a concentration of 100 microM, ERK1/2 activity significantly increased. VEGF produced a time- and concentration-dependent activation of ERK1/2. Maximal activity was obtained after 5 min of stimulation at a concentration of 10 ng/ml. The specific MAPK kinase inhibitor PD 98059 abolished ERK1/2 activation and endothelial cell proliferation in a concentration-dependent manner in response to VEGF and sodium nitroprusside. The NO synthase inhibitor Nomega-monomethyl-L-arginine, as well as the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, blocked the activation of ERK1/2 induced by VEGF, suggesting that NO and cGMP contributed to the VEGF-dependent ERK1/2 activation. These results demonstrate for the first time that kinase-derivative receptor activation triggers the NO synthase/guanylate cyclase pathway to activate the MAPK cascade and substantiates the hypothesis that the activation of ERK1/2 is necessary for VEGF-induced endothelial cell proliferation.
Asunto(s)
Factores de Crecimiento Endotelial/farmacología , Endotelio Vascular/efectos de los fármacos , Linfocinas/farmacología , Óxido Nítrico/farmacología , Calcio/farmacología , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , División Celular/fisiología , Células Cultivadas , Endotelio Vascular/crecimiento & desarrollo , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Flavonoides , Guanilato Ciclasa/antagonistas & inhibidores , Quinasas de Proteína Quinasa Activadas por Mitógenos , Óxido Nítrico Sintasa/antagonistas & inhibidores , Nitroprusiato/farmacología , Oxadiazoles/farmacología , Inhibidores de Proteínas Quinasas , Quinoxalinas/farmacología , Proteínas Tirosina Quinasas Receptoras/fisiología , Receptores de Factores de Crecimiento/fisiología , Receptores de Factores de Crecimiento Endotelial Vascular , Transducción de Señal/fisiología , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular , omega-N-Metilarginina/farmacologíaRESUMEN
We have assessed the role of soluble P-selectin in promoting endothelial cell migration. Human endothelial cells (HUVEC) and bovine microvascular endothelial cells (CVEC) were assessed for migration in the Neuroprobe 48-well microchemotaxis chamber. Soluble P-selectin promoted a dose-dependent (0.1-10 nM) migration of both cell types, with maximal response at 10 nM, producing approximately 60% increment over basal migration. Anti-P-selectin monoclonal antibody (5 microg/ml) selectively blocked P-selectin induced migration. Fibronectin and collagen were essential to disclose the migration induced by P-selectin. It is suggested that at vascular level in the presence of modifications of the extracellular matrix milieu, the production of soluble P-selectin could contribute to angiogenesis by promoting endothelial cell migration.
Asunto(s)
Endotelio Vascular/citología , Selectina-P/farmacología , Animales , Bovinos , Movimiento Celular/efectos de los fármacos , Matriz Extracelular/fisiología , Humanos , Venas Umbilicales/citologíaRESUMEN
Systemic administration of the nitric oxide (NO) synthase inhibitor Nomega-nitro--arginine methyl ester (L-NAME) to rabbits bearing a corneal implant blocked vascular endothelial growth factor (VEGF), but not basic fibroblast growth factor (bFGF)-induced angiogenesis. L-NAME completely blocked angiogenesis induced by VEGF-transfected MCF-7 breast carcinoma cells and the cells remained dormant in the cornea. Postcapillary endothelial cell migration and growth induced by VEGF were blocked by both the NO synthase inhibitor Nomega-mono-methyl--arginine and by the guanylate cyclase inhibitor LY 83583. We conclude that NO is a downstream imperative of VEGF-, but not bFGF-induced angiogenesis, and propose that the NO synthase/guanylate cyclase pathway is a potential target for controlling tumor angiogenesis in response to VEGF. Our studies support recent evidence that VEGF and bFGF induce angiogenesis by different mechanistic pathways using the alphavbeta5 and alphavbeta3 integrins, respectively.
Asunto(s)
Córnea/irrigación sanguínea , Factores de Crecimiento Endotelial/fisiología , Inhibidores Enzimáticos/administración & dosificación , Factor 2 de Crecimiento de Fibroblastos/fisiología , Linfocinas/fisiología , NG-Nitroarginina Metil Éster/administración & dosificación , Neovascularización Fisiológica/fisiología , Óxido Nítrico Sintasa/fisiología , Animales , Trasplante de Córnea , Neovascularización Fisiológica/efectos de los fármacos , Óxido Nítrico Sintasa/antagonistas & inhibidores , Conejos , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
We reported previously that NO is responsible for the angiogenesis produced by endothelium-dependent vasodilating peptides. To investigate the mechanisms by which NO controls angiogenesis, NO was assessed for the ability to affect cell proliferation and upregulation of urokinase-type plasminogen activator (uPA) induced by basic fibroblast growth factor (bFGF) when added exogenously to or when produced endogenously by coronary venular endothelial cells (CVECs). The treatment of the cells with the NO donor sodium nitroprusside (NaNp) induced uPA upregulation and cell proliferation, which were prevented by anti-bFGF antibodies. Similarly, the NO-dependent mitogenic activity of the vasodilating peptide substance P (SP) was blocked by anti-bFGF antibodies, thus implicating endogenous bFGF in the NO-induced response. NaNp and SP induced bFGF expression as measured by Western blot analysis of CVEC extracts and by differential reverse transcriptase-polymerase chain reaction of bFGF mRNA. SP-induced upregulation of bFGF was prevented by the NO synthase inhibitor N omega-monomethyl-L-arginine. We conclude that NO promotes cell proliferation and uPA upregulation in CVECs by inducing endogenous bFGF and that this pathway mediates the angiogenetic response to the vasoactive neuropeptide SP. This signaling paradigm may provide an important link between shear rate, NO, bFGF, and coronary angiogenesis.
Asunto(s)
Vasos Coronarios/metabolismo , Endotelio Vascular/metabolismo , Factor 2 de Crecimiento de Fibroblastos/fisiología , Óxido Nítrico/farmacología , Activadores Plasminogénicos/biosíntesis , Activador de Plasminógeno de Tipo Uroquinasa/biosíntesis , División Celular/efectos de los fármacos , Línea Celular , Vasos Coronarios/citología , Vasos Coronarios/efectos de los fármacos , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Nitroprusiato/farmacología , Vénulas/citología , Vénulas/metabolismoRESUMEN
The placental-derived growth factor (PIGF) is a dimeric glycoprotein showing a high degree of sequence similarity to the vascular endothelial growth factor. Alternative splicing of the PIGF primary transcript gives rise to two forms, named PIGF-1 and PIGF-2, which differ only in the insertion of a highly basic 21-amino acid stretch at the carboxyl end. The presence of the PIGF mRNA in thyroid, placenta, lung, and goiter has indicated the tissues where this factor functions. However, the role of PIGF in vascular development has not yet been clearly established. In the present study, we described the purification of PIGF-1 from overexpressing eukaryotic cells and then measured the angiogenic activity of the purified PIGF-1 in vivo in the rabbit cornea and the chick chorioallantoic membrane assays. In both in vivo assays, PIGF-1 induced a strong neovascularization process that was blocked by affinity-purified anti-PIGF-1 antibody. In the avascular cornea, PIGF-1 induced angiogenesis in a dose-dependent manner and seemed to be at least as effective (if not more effective) than vascular endothelial growth factor and basic fibroblast growth factor under the same conditions and at the same concentration. PIGF-1 was shown to induce cell growth and migration of endothelial cells from bovine coronary postcapillary venules and from human umbilical veins. In these two in vitro assays, PIGF-1 seemed to have a comparable effect to that of vascular endothelial growth factor and basic fibroblast growth factor on the cultured microvascular endothelium (eg, capillary venule endothelial cells). In summary, this is the first study to demonstrate that PIGF-1 can induce angiogenesis in vivo and stimulate the migration and proliferation of endothelial cells in vitro.